224 related articles for article (PubMed ID: 20635926)
1. Potential of anti-Candida antibodies in immunoprophylaxis.
Cabezas J; Albaina O; Montañez D; Sevilla MJ; Moragues MD; Pontón J
Immunotherapy; 2010 Mar; 2(2):171-83. PubMed ID: 20635926
[TBL] [Abstract][Full Text] [Related]
2. Plant production of anti-β-glucan antibodies for immunotherapy of fungal infections in humans.
Capodicasa C; Chiani P; Bromuro C; De Bernardis F; Catellani M; Palma AS; Liu Y; Feizi T; Cassone A; Benvenuto E; Torosantucci A
Plant Biotechnol J; 2011 Sep; 9(7):776-87. PubMed ID: 21265996
[TBL] [Abstract][Full Text] [Related]
3. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.
Pachl J; Svoboda P; Jacobs F; Vandewoude K; van der Hoven B; Spronk P; Masterson G; Malbrain M; Aoun M; Garbino J; Takala J; Drgona L; Burnie J; Matthews R;
Clin Infect Dis; 2006 May; 42(10):1404-13. PubMed ID: 16619152
[TBL] [Abstract][Full Text] [Related]
4. Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis.
Xin H; Cutler JE
Clin Vaccine Immunol; 2011 Oct; 18(10):1656-67. PubMed ID: 21832099
[TBL] [Abstract][Full Text] [Related]
5. Increased resistance in BALB/c mice to reinfection with Candida albicans is due to immunoneutralization of a virulence-associated immunomodulatory protein.
Tavares D; Ferreira P; Arala-Chaves M
Microbiology (Reading); 2003 Feb; 149(Pt 2):333-339. PubMed ID: 12624195
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the usefulness of anti-glyceraldehyde-3-phosphate dehydrogenase antibodies as a treatment for invasive candidiasis in a murine model.
Gil ML; Dagan S; Eren R; Gozalbo D
Antonie Van Leeuwenhoek; 2006; 89(3-4):345-50. PubMed ID: 16779630
[TBL] [Abstract][Full Text] [Related]
7. Active immunizations with peptide-DC vaccines and passive transfer with antibodies protect neutropenic mice against disseminated candidiasis.
Xin H
Vaccine; 2016 Jan; 34(2):245-251. PubMed ID: 26620842
[TBL] [Abstract][Full Text] [Related]
8. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.
Matthews RC; Rigg G; Hodgetts S; Carter T; Chapman C; Gregory C; Illidge C; Burnie J
Antimicrob Agents Chemother; 2003 Jul; 47(7):2208-16. PubMed ID: 12821470
[TBL] [Abstract][Full Text] [Related]
9. Antifungal antibodies: a new approach to the treatment of systemic candidiasis.
Matthews R; Burnie J
Curr Opin Investig Drugs; 2001 Apr; 2(4):472-6. PubMed ID: 11566001
[TBL] [Abstract][Full Text] [Related]
10. Novel Intravenous Immunoglobulin Therapy for the Prevention and Treatment of Candida auris and Candida albicans Disseminated Candidiasis.
Xin H; Rosario-Colon JA; Eberle K
mSphere; 2023 Feb; 8(1):e0058422. PubMed ID: 36688668
[TBL] [Abstract][Full Text] [Related]
11. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine.
Bromuro C; Torosantucci A; Chiani P; Conti S; Polonelli L; Cassone A
Infect Immun; 2002 Oct; 70(10):5462-70. PubMed ID: 12228271
[TBL] [Abstract][Full Text] [Related]
12. Recombinant antibodies: a natural partner in combinatorial antifungal therapy.
Matthews RC; Burnie JP
Vaccine; 2004 Feb; 22(7):865-71. PubMed ID: 15040939
[TBL] [Abstract][Full Text] [Related]
13. Treatment of a critically ill child with disseminated Candida glabrata with a recombinant human antibody specific for fungal heat shock protein 90 and liposomal amphotericin B, caspofungin, and voriconazole.
Sutherland A; Ellis D
Pediatr Crit Care Med; 2008 Jul; 9(4):e23-5. PubMed ID: 18843247
[TBL] [Abstract][Full Text] [Related]
14. [Advances in the diagnosis and treatment of yeast infections: role of the new antifungal agents].
Pemán J; Almirante B
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 13():38-46. PubMed ID: 19100166
[TBL] [Abstract][Full Text] [Related]
15. The role of hsp90 in fungal infection.
Matthews R; Burnie J
Immunol Today; 1992 Sep; 13(9):345-8. PubMed ID: 1466751
[TBL] [Abstract][Full Text] [Related]
16. Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis.
Louie A; Stein DS; Zack JZ; Liu W; Conde H; Fregeau C; Vanscoy BD; Drusano GL
Antimicrob Agents Chemother; 2011 Jul; 55(7):3295-304. PubMed ID: 21502626
[TBL] [Abstract][Full Text] [Related]
17. Saccharomyces as a vaccine against systemic candidiasis.
Liu M; Clemons KV; Johansen ME; Martinez M; Chen V; Stevens DA
Immunol Invest; 2012; 41(8):847-55. PubMed ID: 22686468
[TBL] [Abstract][Full Text] [Related]
18. Candida antigens and immune responses: implications for a vaccine.
Moragues MD; Rementeria A; Sevilla MJ; Eraso E; Quindos G
Expert Rev Vaccines; 2014 Aug; 13(8):1001-12. PubMed ID: 24957934
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic potential of (1,3)-beta-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients.
Pazos C; Moragues MD; Quindós G; Pontón J; del Palacio A
Rev Iberoam Micol; 2006 Dec; 23(4):209-15. PubMed ID: 17388644
[TBL] [Abstract][Full Text] [Related]
20. A novel glyco-conjugate vaccine against fungal pathogens.
Torosantucci A; Bromuro C; Chiani P; De Bernardis F; Berti F; Galli C; Norelli F; Bellucci C; Polonelli L; Costantino P; Rappuoli R; Cassone A
J Exp Med; 2005 Sep; 202(5):597-606. PubMed ID: 16147975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
